Slingshot members are tracking this event:

OPK's Phase 1/2a Study to Assess FVIIa (MOD-5014) in Adult Men With Hemophilia A or B set for March 2017 primary completion date

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Update on Aug 8 2017:
• Phase 2a trial for intravenously administered Factor VII-CTP and Phase 1 trial for subcutaneously administered Factor VII-CTP ongoing.  
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 28, 2018
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Hemophilia A, Hemophilia B, Phase 1/2 Study